Ernexa Therapeutics (NASDAQ:ERNA) Trading 5.1% Higher – Should You Buy?

Posted by Defense World Staff on Jan 23rd, 2026

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) shares rose 5.1% during mid-day trading on Thursday . The company traded as high as $1.26 and last traded at $1.24. Approximately 64,433 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 317,420 shares. The stock had previously closed at $1.18.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on ERNA

Ernexa Therapeutics Stock Performance

The firm has a market cap of $9.73 million, a price-to-earnings ratio of -0.41 and a beta of 6.25. The company has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.44.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.